The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – NRG-GI007
Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma Who Are Not Candidates for Surgery
NRG Oncology
Ku, Geoffrey Yuyat
(646) 888-4588
Phase I/II – 10313
A Phase IB and Randomized Open-Label Phase II Study of M6620 in Combination with Carboplatin/Gemcitabine/Avelumab in Patients with Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
University of Pittsburgh Cancer Institute LAO
Villaruz, Liza C.
(412) 648-6577
Phase II – 10300
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
Yale University Cancer Center LAO
Zeidan, Amer M.
(203) 737-2572
Phase II – APEC1621M
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations
Children’s Oncology Group
Pratilas, Christine Anne
(443) 287-8623
Phase II – EA5191
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
ECOG-ACRIN Cancer Research Group
Neal, Joel William
(650) 725-3081
Phase II – TRC-10446
Tocilizumab in Hospitalized Cancer Patients with Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)
National Cancer Institute
Little, Richard Fowler
(240) 276-6560
Phase III – A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Alliance for Clinical Trials in Oncology
Sands, Jacob M.
(671) 632-6049
Phase III – NRG-CC005
FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
NRG Oncology
Schoen, Robert E.
(412) 648-9825
Phase III – S1925
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
SWOG
Stephens, Deborah Marie
(801) 587-4354
Phase III – WF-1901
Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
Wake Forest NCORP Research Base
Penzien, Donald B.
(336) 716-4382
Phase Other – NCICOVID
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
National Cancer Institute
Korde, Larissa A.
(240) 276-6077
